Trials / Completed
CompletedNCT06777602
A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)
An Open-label Phase 1 IV Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]MK-5475 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] MK-5475 | \[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1. |
Timeline
- Start date
- 2022-08-15
- Primary completion
- 2022-09-30
- Completion
- 2022-10-25
- First posted
- 2025-01-16
- Last updated
- 2025-10-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06777602. Inclusion in this directory is not an endorsement.